SCHEMBL5366386

SCHEMBL5366386

Cc1c(Br)ccc2c1C(=Cc1cc(Cl)c(OCc3ccccc3)c(C(C)(C)C)c1)C(=O)N2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 5/20 0.49
EGFR P00533 4/20 0.49
PPARG P37231 2/20 0.42
IGF1R P08069 1/20 0.41
RAF1 P04049 1/20 0.38
PLK4 O00444 1/20 0.37
PLK1 P53350 1/20 0.37
HPGD P15428 1/20 0.36
LRRK2 Q5S007 4/20 0.36
SIRT2 Q8IXJ6 2/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
ACP1 P24666 1/20 0.36
SIRT1 Q96EB6 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
SIRT5 Q9NXA8 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374088 0.94 ERBB2 (0.53) ERBB2EGFRPPARGIGF1RRAF1
SCHEMBL5363012 0.92 ERBB2 (0.56) ERBB2EGFRPPARGIGF1RRAF1
SCHEMBL5358782 0.90 ERBB2 (0.49) ERBB2EGFRPPARGIGF1RRAF1
SCHEMBL7134258 0.88 ERBB2 (0.45) ERBB2EGFRPPARGIGF1RHPGD
SCHEMBL5376941 0.85 ERBB2 (0.61) ERBB2EGFRIGF1RRAF1PLK4
SCHEMBL5364236 0.85 ERBB2 (0.52) ERBB2EGFRPPARGIGF1RHPGD
SCHEMBL5368842 0.84 LRRK2 (0.43) ERBB2EGFRPPARGRAF1PLK4
SCHEMBL5358336 0.81 ERBB2 (0.52) ERBB2EGFRPPARGIGF1RRAF1
SCHEMBL7139003 0.81 ERBB2 (0.48) ERBB2EGFRPPARGIGF1RSIRT2
SCHEMBL5365798 0.81 ERBB2 (0.48) ERBB2EGFRPPARGIGF1RPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK ERBB2 19/4885EGFR 286/4885PPARG 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.